MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care
MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
- MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
- This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
- MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
- Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.